At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of B-cell CLL with peripheral blood absolute lymphocyte count >5,000/mm³
- ✓Small- to moderate-size lymphocytes with <55% prolymphocytes, atypical lymphocytes, or lymphoblasts
- ✓B-CLL phenotype expressing CD20 and CD52
- ✓B-cell shares B-cell antigens with CD5 in absence of pan-T-cell markers (CD-3, CD-2)
- ✕Active autoimmune anemia or thrombocytopenia
- ✕Active infection requiring oral or intravenous antibiotics
- ✕Second malignancy other than basal cell carcinoma of skin or in situ cervical carcinoma, unless curatively treated ≥2 years ago
- ✕Prior cytotoxic therapy (other than corticosteroids)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Alemtuzumab (Campath-1H) and Rituximab (Rituxan) in Patients With Previously Untreated CLL
In Brief
A Phase 2 clinical trial evaluating Alemtuzumab and Rituximab for Leukemia. Completed, enrolled 30 participants across 1 site.
Detailed Summary
RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving alemtuzumab together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects of giving alemtuzumab together with rituximab and to see how well it works in treating patients with previously untreated B-cell chronic lymphocytic leukemia.
Study Details
Timeline
Interventions
Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks
Rituximab administered intravenously at 375mg/m2 every 2 weeks for 18 weeks